阿德福韦酯在不同时间联合聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎患者疗效的比较*

doi:10.3969/j.issn.1672-5069.2015.05.021

Abstract

An Hongjie，He Wenyan,Zhao Chongshan，et al. De novo or at time of decreased serum viral load combination of pegylated interferon α-2a and adevir dipivoxil in treatment of patients with HBeAg positive and high HBV DNA levels[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 534-535.

References

[1] 慢性乙型肝炎防治指南（2010年版）.中华医学会肝病学分会和感染病学分会.实用肝脏病杂志，2011，14（2）:81-89.
[2] 陈新月，马丽娜，陶明玲，等.联合抗病毒治疗32例HBeAg阳性慢性乙型肝炎患者表明抗原转换初步探讨.中华传染病杂志，2008，26（10）:597-603.
[3] 何艳，唐晓鹏，郑宣鹤，等.干扰素联合核苷（酸）类似物治疗慢性乙型肝炎的疗效观察.临床肝胆病杂志，2013，29（2）:114-116，119.
[4] 林琪，余雪平，苏智军，等.核苷（酸）类似物治疗慢性乙型肝炎部分应答后加用α干扰素继续治疗疗效分析.实用肝脏病杂志，2013，16（3）:232-234.
[5] 陈海鸥，刘洪娟，胡小萱.德福韦酯联合Peg-干扰素α-2a治疗高病毒载量慢性乙型肝炎患者的疗效观察.胃肠病学和肝病学杂志，2013，22（5）:456-458.
[6] 王兵，贾红宇，梁柱石，等. 普通干扰素α-2b联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎患者多中心随机开放对照临床研究.实用肝脏病杂志，2014，17（4）:372-375.
[7] 杨才勇，刘胜昔，李奎，等.干扰素α-2b联合阿德福韦酯治疗慢性乙型肝炎疗效观察.传染病信息杂志，2010，23（4）:234-236.
[8] 成娟，王大伟，刑陈，等. 聚乙二醇化干扰素α-2a治疗阿德福韦酯经治的e抗原阳性慢性乙型肝炎临床观察.肝脏，2014，19（9）:689-691.
[9] 王亚东，赵彩彦，申川，等.Peg-干扰素α-2a联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎患者优化策略初探.中国病毒病杂志，2011，1：58-63.
[10] 李文兵，丁继光，孙庆丰，等.Peg-干扰素α-2a与阿德福韦酯联合治疗HBeAg阳性慢性乙型肝炎患者的研究.中华医院感染学杂志，2013，23:1250-1252.
[11] Liaw YF，Chu CM，Hepatitis B virus infection.Lancet，2009，373（9663）:582-592.
[12] Chu CM， Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther， 2010，15（2）:133-143.
[13] Europea Association for the Study of the Liver. EASL clinical practice guidelines:management of cholostatic liver diseases. J Hepatol，2009，51（2）:237-267.
[14] 毛青.慢性乙型肝炎病毒感染者抗病毒治疗的现状与思考.实用肝脏病杂志，2013，16（4）:289-292.

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.

De novo or at time of decreased serum viral load combination of pegylated interferon α-2a and adevir dipivoxil in treatment of patients with HBeAg positive and high HBV DNA levels

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments